Skip to main content
. 2021 Aug 25;9(8):e3770. doi: 10.1097/GOX.0000000000003770

Table 1.

Study Details, Lymphedema Status, and Outcome Measures15–30

Authors (y) Study Type No. Patients No. Upper Limbs Lymphedema Type (PL vs SL) Duration of Lymphedema before LVA Intervention Anastomoses (Mean #) Measurement Method Follow-up Time (Mean) Objective Improvement in % Patients Subjective Improvement in % Patients
AlJindan et al (2019)15 Prospective 20 20 PL and SL 54.1 mo LVA (8 end to end, 12 side to end) + ICG 3.7 Limb circumference 16.5 mo 100
Salgarello et al (2018)16 Prospective 44 PL and SL 56 mo LVA + ICG 3.38 LyMQoL questionnaire 8.5 mo 61
Gentileschi et al (2017)17 Prospective 16 16 PL and SL 5.7 y LVA + ICG 1.8 Circumference measurements, LYMQoL questionnaire 12.1 mo 88 94
Poumellec et al (2017)18 Prospective 31 SL LVA 3.75 Circumference measurements, QoL questionnaire 12.7 mo 93.5 84
Winters et al (2017)19 Prospective 29 29 SL 9 mo LVA (end to end, end to side, and invagination) 1.67 Volume measurements, QoL questionnaire 12 mo 97 53
Pereira et al (2018)20 Retrospective 8 8 SL 4.61 y LVA + ICG 2.67 Circumference measurements, volumetric estimation 27.4 mo 100 100
Yamamoto et al (2014)21 Prospective 3 3 SL LVA + ICG 1.6 Circumference measurements 6 mo 100
Lee et al (2017)22 Retrospective 3 3 SL 7 y End to end LVA 2.7 Volume measurements 41.8 mo 100% at 12 mo, 67% at 24 mo Did not separate by UE vs LE
Ayesteray et al (2013)23 Prospective 20 20 PL and SL 3.2 y LVA + patent blue Circumference measurements and volumetric estimation 12 mo 85 90
Cornelissen et al (2017)24 Prospective 20 SL 6 y LVA + ICG 1.5 Lymph-ICF QoL questionnaire 7.8 mo 85
Damstra et al (2009)25 Prospective 10 11 SL 5.3 y LVA (end to end) + lymphoscintigr aphy Volume measurements, SF-36 QoL questionnaire 8 y 0 50
Chang (2010)26 Prospective 20 20 SL 4.8 y LVA 3.5 Volumetric measurement 12 mos 65 85
Ayestaray and Bekara (2014)27 Prospective 12 12 PL and SL 4.6 y Pi-shaped LVA with patent blue 5.4 Circumfrence measurements, QoL questionnaire Did not separate by UE vs LE 100
Narushima et al. (2010)29 Prospective 2 2 SL 7 y LVA + ICG with intravascular stenting 5 Girth measurements 8.9 mo Did not separate by UE vs LE
Mihara et al (2014)29 Retrospective 11 11 PL and SL LVA + ICG 3 Frequency of cellulitis At least 1 y Did not separate by UE vs LE
Chang et al (2013)30 Prospective 100 89 SL 3.5 y LVA + ICG Volume differential (excess volume of the edematous limb compared to the unaffected limb) 30.4 mo 74 96